top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

M&As announced YTD in 2024

M&A highlights from previous weeks…👇

YTD Summary:

Number Announced:      31

Q1 2024 # Announced:  18

Q2 2024 # Announced:  13


Acquired By: Biogen

Announcement Date: May 22, 2024

Acquisition Price: $1.15B + $650M potential milestone payment

Acquisition Date (Closed): Pending

Lead Asset: Felzartamab 

Lead Asset Stage: Phase 2

Indication: Immune-mediated diseases


Acquired By: Johnson & Johnson

Announcement Date: May 16, 2024

Acquisition Price: $850M + potential milestone payment

Acquisition Date (Closed): Pending

Lead Asset: PX128 

Lead Asset Stage: Phase 1

Indication: Atopic dermatitis and Asthma

Reneo Pharmaceuticals & OnKure (Merger)  

Announcement Date: May 13, 2024

Merger Date (Closed): Pending

Lead Asset: OKI-219 

Lead Asset Stage: Phase 1

Lead Asset Indication: Solid tumors


Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more

Article History:

RF, DV, DG (05/23/24)

This article is not investment or legal advice.


bottom of page